PABPC1P10: A Potential Drug Target and Biomarker (G285314)

Target Name: PABPC1P10

NCBI ID: G285314

PABPC1P10

Other Name(s): PABPL1 | D3S3192 | Poly(A) binding protein, cytoplasmic 1 pseudogene 10 | poly(A) binding protein cytoplasmic 1 pseudogene 10 | PAB1

PABPC1P10: A Potential Drug Target and Biomarker

PABPC1P10, also known as PABPL1, is a protein that is expressed in various tissues and cells in the body. Its unique structure and expression pattern have caught the attention of researchers due to its potential role in disease. This article will explore the biology of PABPC1P10, its potential as a drug target, and its role as a biomarker in various diseases.

The PABPC1P10 protein is a member of the PABP family, which is known for its role in the regulation of intracellular signaling pathways. PABPC1P10 is a 10-kDa protein that is expressed in various tissues, including the brain, heart, liver, and kidneys. It is primarily localized to the endoplasmic reticulum (ER) and is involved in the formation of the endoplasmic reticulum-derived vesicles (ERVs), which are involved in the delivery of proteins to various cell types.

One of the unique features of PABPC1P10 is its expression pattern. Unlike many other proteins, PABPC1P10 is not expressed in all tissues and cells. Instead, it is primarily expressed in the brain, where it is involved in the regulation of various signaling pathways that are critical for brain development and function.

The role of PABPC1P10 in disease is still being explored, but its potential as a drug target and biomarker is significant. PABPC1P10 has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

In cancer, PABPC1P10 has been shown to promote the growth and survival of various cancer cell types. For example, studies have shown that PABPC1P10 can promote the growth of breast cancer cells and enhance the sensitivity of cancer cells to chemotherapy.

In neurodegenerative diseases, PABPC1P10 has been shown to contribute to the development and progression of various neurological disorders. For example, studies have shown that PABPC1P10 is involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In autoimmune diseases, PABPC1P10 has been shown to play a role in the development and progression of various autoimmune diseases. For example, studies have shown that PABPC1P10 is involved in the development of rheumatoid arthritis and other autoimmune diseases.

In addition to its potential role in disease, PABPC1P10 also has potential as a biomarker. Its unique expression pattern and involvement in various tissues make it an attractive candidate for diagnostic and therapeutic applications.

PABPC1P10 can be used as a biomarker for various diseases due to its unique expression pattern. Its expression is primarily localized to the ER and is involved in the delivery of proteins to various cell types, which makes it an attractive candidate for diagnostic applications.

In addition to its potential as a biomarker, PABPC1P10 also has potential as a drug target. Its unique structure and expression pattern make it an attractive target for small molecules and other therapeutic agents.

Overall, PABPC1P10 is a protein that has the potential to be a drug target and biomarker in various diseases. Further research is needed to fully understand its role in disease and its potential as a therapeutic agent.

Protein Name: Poly(A) Binding Protein Cytoplasmic 1 Pseudogene 10

The "PABPC1P10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PABPC1P10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets